Drug Discovery World

APRIL 17, 2024

The Bios Innovation Circle is aimed at empowering the success of biotech and life science companies, investors, pharmaceutical companies, clinical research organisations and other innovative solution providers to accelerate development and bring life-saving treatments to the market faster.

Science 130

Science Pharmaceutical Companies Clinical Research Therapies 130

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. Could you give us an overview of the Lineage platform?

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Discovery World

MARCH 14, 2024

Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). Patients with bone-only metastatic disease are also included in the study.

Clinical Trials 130

Clinical Trials Pharmaceutical Companies Drugs FDA 130

Drug Discovery World

JULY 5, 2023

Through such therapies, slowly, hesitatingly, some people are using the word ‘cure’ with a few individual cancer patients, which is something the field has avoided for decades. These types of therapies are often more effective and have fewer side effects. These types of therapies are often more effective and have fewer side effects.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? This can present challenges when attempting to recruit an enriched patient population for clinical trials. The lack of heterogeneity can introduce significant risk into mid- to late-stage studies.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery World

DECEMBER 28, 2023

But I also recall other moments that made me painfully aware that significant efforts are needed in the treatment of children with cancer. To date, much of the conversation in oncology research and development has focused on treatments for adults. I was impressed by his determination and proud to be part of his team.

Research 130

Research Clinical Trials Hospitals Trials 130

Drug Target Review

AUGUST 6, 2024

Autoimmune diseases : Rheumatoid Arthritis : ADCs targeting specific immune cells or inflammatory mediators can provide more precise treatment options with potentially fewer side effects. Obesity : By targeting adipose tissue or specific metabolic pathways, ADCs could offer new treatments for obesity and related metabolic disorders.

Pharmaceutical Companies 117

Pharmaceutical Companies Therapies Disease Treatment 117

Drug Discovery World

SEPTEMBER 26, 2022

It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. Perhaps the biggest benefit drug repurposing brings is its potential to get treatments to patients faster than traditional means of drug discovery. However, challenges remain.

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

JUNE 2, 2023

AI-designed monoclonal antibody ‘redirects’ the immune system Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The post This week in drug discovery (29 May – 2 June) appeared first on Drug Discovery World (DDW).

Pharmaceutical Companies 130

Pharmaceutical Companies Clinical Trials Drugs Pharmaceuticals 130

DrugBank

MARCH 7, 2024

Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies 80

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 80

Drug Discovery World

JULY 15, 2024

This bodes well for potential future research and therapies,” she adds. Ariceum was presenting a poster demonstrating findings on the discovery of novel macrocyclic peptide radioligands for tumour therapy by mRNA display. András Strassz expressed that at Heidelberg Pharma, the goal is to make Amanitin available as a cancer therapy.

Research 130

Research Clinical Pharmacology Therapies RNA 130

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

Drug Discovery World

SEPTEMBER 28, 2023

The microbiome also is being explored as a metric to gauge therapeutic efficacy of symptom-based treatment for these conditions. For example, one clinical trial is using PCR to assess microbiota composition before and after a series of interventions for PCOS 7.

Clinical Trials 162

Clinical Trials Regulations Trials Drug Development 162

Drug Discovery World

AUGUST 1, 2023

The deal makes sense given Catamaran’s focus on using synthetic biology and non-viral cell engineering to develop highly potent allogeneic, cryopreserved CAR-NK cell therapies that target challenging cancers, including solid tumours.

Drugs 130

Drugs Licensing Licensing Engineering 130

The Pharma Data

OCTOBER 9, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the U.S. The committee also voted unanimously to recommend use of maribavir for the treatment of refractory CMV infection and disease without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

FDA 52

FDA Treatment Disease Pharmaceutical Companies 52

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. 2 PsA can be a challenging disease to treat especially in younger populations, reinforcing the need for additional treatment options. A decision from the U.S.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. In addition, health-related quality of life (HRQoL), per total Functional Assessment of Cancer Therapy–Prostate (FACT-P), continued to be maintained with ERLEADA ®.

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

FEBRUARY 25, 2021

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan. – Phase 1/2 immunogenicity and safety trials designed to include 200 healthy Japanese adults followed for 12 months after second vaccination. TAK-919 clinical trial. TAK-019 clinical trial.

Clinical Trials 52

Clinical Trials Trials Vaccine Pharmaceutical Companies 52

Drug Discovery World

JULY 18, 2022

“I love innovation and working with incredible minds in the pharmaceutical and life science fields who create amazing new technologies and methods of treatment,” says Groetken. The next phase, however, is the utilisation of AI and big data as to precision therapy. As a result, better technologies and treatments are developed.

Clinical Trials 130

Clinical Trials Therapies Pharmaceuticals Science 130

Drug Discovery World

JANUARY 22, 2024

Despite the distance the biomedical world has come when it comes to improving protective measures for people participating in clinical trials, Welsh says there are still many areas where the goals of public health and pharmaceutical/medical corporations are in conflict.

Science 162

Science Clinical Trials Disease Research 162

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion, Mounjaro's performance is a testament to the booming demand for innovative therapies targeting diabetes and obesity.  With sales soaring to $2.2 for this class of drugs.

Pharmaceutical Companies 67

Pharmaceutical Companies Pharmaceuticals Marketing Treatment 67

The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. John Reed , MD , Ph. Nicholas Galakatos, Ph.D.

Science 52

Science Treatment Clinical Trials Therapies 52

The Pharma Data

MARCH 27, 2023

Entyvio ® should be used only in patients with inadequate response to conventional treatment. This approval is based on the MLN0002SC-3027 and MLN0002SC-3030 clinical trials, which are international Phase III trials to evaluate the efficacy and safety of Entyvio SC as a maintenance therapy.

Treatment 40

Treatment Marketing Pharmaceutical Companies Immune Response 40

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Virus 40

The Pharma Data

MARCH 22, 2021

VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021. Novartis is committed to reimagining prostate cancer through targeted radioligand therapy with 177 Lu-PSMA-617. The safety profile was consistent with data reported in previous clinical studies 1.

Therapies 52

Therapies Treatment Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 23, 2021

Today’s approval helps meet a significant unmet medical need by providing a treatment option for this patient population.”. In the study, 352 transplant recipients with CMV infections who did not respond (with or without resistance) to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks.

FDA Approval 52

FDA Approval Treatment FDA DNA 52

The Pharma Data

MARCH 7, 2022

Astellas”) today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions.

Treatment 52

Treatment Clinical Trials Trials Pharmaceutical Companies 52

Drug Discovery World

JULY 2, 2024

In another example, university of Basel spin-off T3 Pharma reached Phase I development of a cancer therapy that harnesses the natural behaviours of live bacteria before being acquired by Boehringer Ingelheim for $509m at the end of 2023. Three years ago, we started our venture into the radiotherapy space.

Science 147

Science Drugs Clinical Trials Licensing 147

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

APRIL 27, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that that the U.S. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations. About the Phase 1/2 Trial. and around the globe.”. In 2019, the U.S.

FDA 52

FDA Treatment Pharmaceutical Companies FDA Approval 52

The Pharma Data

DECEMBER 3, 2020

The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

Drug Discovery World

OCTOBER 20, 2022

These agents have remained the top selling pharmaceuticals in the therapeutic category in recent years and, due to Japan’s aging society, continue on an upward trajectory 1. . To this end, pharmaceutical company ViiV Healthcare received approval in Japan for its long-acting HIV treatment in May 2022 5. Overview .

Drugs 130

Drugs International Science Government 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

JUNE 25, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?) protofibril antibody for the treatment of Alzheimer’s disease (AD). 1 The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta (A?)

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

JANUARY 15, 2021

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Comenzo, M.D., Director, John C. Approximately 4,500 people in the U.S.

FDA Approval 52

FDA Approval FDA Treatment Pharmaceutical Companies 52

The Pharma Data

JANUARY 14, 2021

(NASDAQ: FPRX) today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. The ASCO GI presentation slides are available on the company’s website.

Trials 52

Trials Treatment Therapies Clinical Trials 52